FI3777842T3 - Melatoniinin minitabletteja ja menetelmä niiden valmistamiseksi - Google Patents
Melatoniinin minitabletteja ja menetelmä niiden valmistamiseksi Download PDFInfo
- Publication number
- FI3777842T3 FI3777842T3 FIEP20195788.3T FI20195788T FI3777842T3 FI 3777842 T3 FI3777842 T3 FI 3777842T3 FI 20195788 T FI20195788 T FI 20195788T FI 3777842 T3 FI3777842 T3 FI 3777842T3
- Authority
- FI
- Finland
- Prior art keywords
- mini
- melatonin
- tablet
- coating
- delayed
- Prior art date
Links
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 title claims 22
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 title claims 22
- 229960003987 melatonin Drugs 0.000 title claims 22
- 239000008185 minitablet Substances 0.000 title claims 9
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000003826 tablet Substances 0.000 claims 14
- 229920001577 copolymer Polymers 0.000 claims 10
- 238000000034 method Methods 0.000 claims 8
- 239000011248 coating agent Substances 0.000 claims 7
- 238000000576 coating method Methods 0.000 claims 7
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 4
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 claims 4
- 235000019700 dicalcium phosphate Nutrition 0.000 claims 4
- 229960001021 lactose monohydrate Drugs 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- 208000029560 autism spectrum disease Diseases 0.000 claims 2
- 230000006835 compression Effects 0.000 claims 2
- 238000007906 compression Methods 0.000 claims 2
- 238000009505 enteric coating Methods 0.000 claims 2
- 239000002702 enteric coating Substances 0.000 claims 2
- 238000009501 film coating Methods 0.000 claims 2
- 239000007888 film coating Substances 0.000 claims 2
- 229960001375 lactose Drugs 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 238000009495 sugar coating Methods 0.000 claims 2
- 208000019505 Deglutition disease Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662415014P | 2016-10-31 | 2016-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3777842T3 true FI3777842T3 (fi) | 2025-02-11 |
Family
ID=57482481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20195788.3T FI3777842T3 (fi) | 2016-10-31 | 2016-11-29 | Melatoniinin minitabletteja ja menetelmä niiden valmistamiseksi |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10722494B2 (enExample) |
| EP (3) | EP3777842B1 (enExample) |
| JP (1) | JP6830156B2 (enExample) |
| KR (1) | KR102167190B1 (enExample) |
| CN (1) | CN109922795B (enExample) |
| AU (6) | AU2016426598C1 (enExample) |
| CA (1) | CA3040027C (enExample) |
| CY (1) | CY1123449T1 (enExample) |
| DK (2) | DK3337462T3 (enExample) |
| ES (2) | ES2828034T3 (enExample) |
| FI (1) | FI3777842T3 (enExample) |
| HR (2) | HRP20250166T1 (enExample) |
| HU (2) | HUE051362T2 (enExample) |
| IL (1) | IL262537B (enExample) |
| LT (2) | LT3777842T (enExample) |
| MX (1) | MX386987B (enExample) |
| NZ (1) | NZ747702A (enExample) |
| PL (2) | PL3777842T3 (enExample) |
| PT (2) | PT3337462T (enExample) |
| RS (2) | RS66471B1 (enExample) |
| SG (1) | SG11201903829PA (enExample) |
| SI (2) | SI3777842T1 (enExample) |
| SM (2) | SMT202500046T1 (enExample) |
| TW (1) | TWI787164B (enExample) |
| WO (1) | WO2018078429A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12636255B2 (en) * | 2020-10-23 | 2026-05-26 | Atoz Pharmaceuticals Pvt Ltd | Nongranulated compressed tablets of mesalamine, and process of preparation thereof |
| WO2022092767A1 (ko) * | 2020-10-26 | 2022-05-05 | 일동제약(주) | 옥수수불검화추출물을 포함하는 소형화된 경구투여 제제의 제조방법 및 이에 따라 제조된 소형화 제제 |
| JP2025533153A (ja) | 2022-10-14 | 2025-10-03 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 持続放出性メラトニン組成物 |
| CN117281909A (zh) * | 2023-07-27 | 2023-12-26 | 上海长征医院 | 一种野外条件下诱导快速入睡的组合物及制备方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4600723A (en) | 1983-05-18 | 1986-07-15 | Monash University | Method for minimizing disturbances in circadian rhythms of bodily performance and function |
| DE69229490T2 (de) | 1991-05-09 | 2000-02-17 | Neurim Pharmaceuticals (1991) Ltd., Tel Aviv | Melatonin enthaltende Arzneimittel |
| DK0565296T3 (da) | 1992-04-07 | 1996-12-09 | Neurim Pharma 1991 | Anvendelse af melatonin til fremstilling af et lægemiddel til behandling af godartet prostatahyperplasi |
| US5449683A (en) | 1992-10-01 | 1995-09-12 | Massachussetts Institute Of Technology | Methods of inducing sleep using melatonin |
| WO1995003043A1 (en) * | 1993-07-26 | 1995-02-02 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University | Sustained release oral compositions containing melatonin |
| MD1716C2 (ro) * | 1995-02-01 | 2002-02-28 | Neurim Pharmaceuticals (1991) Ltd. | Utilizare a melatoninei pentru tratamentul pacienţilor dependenţi de benzodiazepine |
| US6469044B1 (en) * | 1995-02-01 | 2002-10-22 | Neurim Pharmaceuticals (1991) Ltd. | Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies |
| FR2762513B1 (fr) * | 1997-04-23 | 2003-08-22 | Permatec Pharma Ag | Comprimes bioadhesifs |
| AU6283299A (en) | 1998-10-01 | 2000-04-17 | Elan Pharma International Limited | Controlled release nanoparticulate compositions |
| EP1064938A1 (en) * | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Pharmaceutical dosage forms for controlled release producing at least a timed pulse |
| IL150190A0 (en) | 2000-01-05 | 2002-12-01 | Neurim Pharma 1991 | Method and formulation for treating resistance to antihypertensives and related conditions |
| US6458384B2 (en) * | 2000-02-23 | 2002-10-01 | Impetus Ag | Pharmaceutical with predetermined activity profile |
| IL144900A (en) | 2001-08-14 | 2013-12-31 | Neurim Pharma 1991 | Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs |
| IL149377A (en) * | 2002-04-28 | 2012-10-31 | Neurim Pharma 1991 | Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds |
| KR20030016215A (ko) * | 2002-07-05 | 2003-02-26 | 뉴림 파머슈티칼스 (1991) 리미티드 | 항고혈압제에 대한 내성 및 관련 질환의 치료를 위한 방법및 제형 |
| AU2004207578B2 (en) * | 2003-01-28 | 2007-06-28 | Collegium Pharmaceutical, Inc. | Multiparticulate compositions of milnacipran for oral administration |
| IL155666A (en) | 2003-04-29 | 2013-12-31 | Neurim Pharma 1991 | Insomnia treatment |
| EP1696959A2 (en) | 2003-12-24 | 2006-09-06 | Sepracor, Inc. | Melatonin combination therapy for improving sleep quality |
| FR2889811B1 (fr) * | 2005-08-19 | 2009-10-09 | Sanofi Aventis Sa | Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique. |
| DE102006006532B4 (de) | 2006-02-10 | 2007-11-08 | Biogenerics Pharma Gmbh | Pharmazeutische Zubereitung |
| WO2008148015A1 (en) | 2007-05-24 | 2008-12-04 | The Trustees Of Columbia University In The City Of New York | Sustained release formulation of melatonin |
| US20100159001A1 (en) * | 2008-12-19 | 2010-06-24 | Cardinal John R | Extended-Release Pharmaceutical Formulations |
| US9532952B2 (en) | 2011-01-28 | 2017-01-03 | Physician's Seal, LLC | Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients |
| US8691275B2 (en) | 2011-01-28 | 2014-04-08 | Zx Pharma, Llc | Controlled-release melatonin compositions and related methods |
| RU2488388C1 (ru) * | 2012-05-24 | 2013-07-27 | Ооо "Валента Интеллект" | Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств |
| EP2949322B1 (en) | 2014-05-28 | 2018-04-25 | Valpharma S.p.A. | Formulation for oral administration comprising melatonin in stable form and method of production thereof |
-
2016
- 2016-11-29 DK DK16805903.8T patent/DK3337462T3/da active
- 2016-11-29 PT PT168059038T patent/PT3337462T/pt unknown
- 2016-11-29 KR KR1020187035251A patent/KR102167190B1/ko active Active
- 2016-11-29 PT PT201957883T patent/PT3777842T/pt unknown
- 2016-11-29 AU AU2016426598A patent/AU2016426598C1/en active Active
- 2016-11-29 EP EP20195788.3A patent/EP3777842B1/en active Active
- 2016-11-29 SM SM20250046T patent/SMT202500046T1/it unknown
- 2016-11-29 EP EP24208766.6A patent/EP4474012A3/en active Pending
- 2016-11-29 JP JP2019519420A patent/JP6830156B2/ja active Active
- 2016-11-29 HU HUE16805903A patent/HUE051362T2/hu unknown
- 2016-11-29 SM SM20200575T patent/SMT202000575T1/it unknown
- 2016-11-29 DK DK20195788.3T patent/DK3777842T3/da active
- 2016-11-29 ES ES16805903T patent/ES2828034T3/es active Active
- 2016-11-29 FI FIEP20195788.3T patent/FI3777842T3/fi not_active Application Discontinuation
- 2016-11-29 CN CN201680090550.4A patent/CN109922795B/zh active Active
- 2016-11-29 LT LTEP20195788.3T patent/LT3777842T/lt unknown
- 2016-11-29 EP EP16805903.8A patent/EP3337462B1/en active Active
- 2016-11-29 HU HUE20195788A patent/HUE070190T2/hu unknown
- 2016-11-29 RS RS20250094A patent/RS66471B1/sr unknown
- 2016-11-29 HR HRP20250166TT patent/HRP20250166T1/hr unknown
- 2016-11-29 CA CA3040027A patent/CA3040027C/en active Active
- 2016-11-29 MX MX2019004736A patent/MX386987B/es unknown
- 2016-11-29 HR HRP20201722TT patent/HRP20201722T1/hr unknown
- 2016-11-29 SI SI201631888T patent/SI3777842T1/sl unknown
- 2016-11-29 PL PL20195788.3T patent/PL3777842T3/pl unknown
- 2016-11-29 NZ NZ747702A patent/NZ747702A/en active IP Right Revival
- 2016-11-29 RS RS20201242A patent/RS61024B1/sr unknown
- 2016-11-29 WO PCT/IB2016/057190 patent/WO2018078429A1/en not_active Ceased
- 2016-11-29 LT LTEP16805903.8T patent/LT3337462T/lt unknown
- 2016-11-29 SG SG11201903829PA patent/SG11201903829PA/en unknown
- 2016-11-29 ES ES20195788T patent/ES3009413T3/es active Active
- 2016-11-29 SI SI201630947T patent/SI3337462T1/sl unknown
- 2016-11-29 PL PL16805903T patent/PL3337462T3/pl unknown
- 2016-12-26 TW TW105143159A patent/TWI787164B/zh active
-
2018
- 2018-10-24 IL IL262537A patent/IL262537B/en active IP Right Grant
- 2018-10-31 US US16/176,338 patent/US10722494B2/en active Active
-
2019
- 2019-01-24 AU AU2019200479A patent/AU2019200479B2/en active Active
- 2019-11-28 AU AU2019101470A patent/AU2019101470B4/en not_active Expired
-
2020
- 2020-06-16 US US16/902,419 patent/US10869857B2/en active Active
- 2020-10-14 CY CY20201100971T patent/CY1123449T1/el unknown
-
2021
- 2021-01-18 AU AU2021200268A patent/AU2021200268A1/en not_active Abandoned
-
2023
- 2023-03-31 AU AU2023202003A patent/AU2023202003A1/en active Pending
-
2025
- 2025-09-18 AU AU2025234204A patent/AU2025234204A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2644942T3 (es) | Métodos y composiciones para el tratamiento del trastorno por déficit de atención | |
| FI3902547T3 (fi) | Csf1r-inhibiittoreita käytettäväksi syövän hoitamisessa | |
| JP2020023518A5 (enExample) | ||
| JP2021008523A (ja) | 過度のフィブリン沈着及び／または血栓形成に関連する病理学的状態の治療または予防のための化合物及び組成物 | |
| BR112019025286A2 (pt) | Métodos e composições para tratamento de sonolência excessiva | |
| FI3936130T3 (fi) | Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon | |
| FI3801536T3 (fi) | Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi | |
| FI4212152T3 (fi) | Sakubitriili-valsartaaniannostusohjelma kroonisen systolisen sydämen vajaatoiminnan hoitoon | |
| BRPI0716436B8 (pt) | sistema de liberação controlada e método para fabricação do mesmo | |
| JP2017510607A5 (enExample) | ||
| KR20090034810A (ko) | 멜라토닌 효능제 치료 | |
| RU2017112308A (ru) | Композиции и способы для лечения бессонницы | |
| JP2018502168A5 (enExample) | ||
| RU2016143979A (ru) | Схема дозирования модулятора s1p с немедленным высвобождением | |
| JP2019529570A5 (enExample) | ||
| HRP20250166T1 (hr) | Mini tablete melatonina i način proizvodnje istih | |
| JP2019533672A5 (enExample) | ||
| RU2018104691A (ru) | Композиции с модифицированным высвобождением ницерголина | |
| JPWO2018193648A1 (ja) | アルカリ性化剤による血液浄化 | |
| Sanchez-Delgado et al. | Role of rifaximin in the treatment of hepatic encephalopathy | |
| MY187270A (en) | Renal insufficiency progression inhibitor, prophylactic agent for renal insufficiency and indoxyl sulfate production inhibitor | |
| JP2503571B2 (ja) | 脳循環代謝改善剤 | |
| Moore et al. | Steady-state pharmacokinetics of extended-release hydromorphone (OROS hydromorphone): a randomized study in healthy volunteers | |
| CN111065389A (zh) | 治疗自身免疫性微脉管疾病的方法 | |
| US20200297659A1 (en) | Methods of diagnosis and treatment involving nitrite |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application lapsed |